F-star Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies July 12, 2023
Shorla Oncology Announces Licensing Agreement and Strategic Partnership for Rights to Market Chemotherapy Drug, PIP-101, in the United States July 12, 2023
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID July 12, 2023
New Positive Interim Ph 3 Data Demonstrating RenovoGem™ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer Announced July 12, 2023
Datopotamab Deruxtecan Met Dual Primary Endpoint Of PFS In Patients With Advanced NSCLC in TROPION-Lung01 Phase 3 Trial July 12, 2023
Botensilimab/Balstilimab Combination Achieves Unprecedented Survival in Advanced Colorectal Cancer July 12, 2023
NEJM Publishes BRUIN Ph 1/2 Trial Data for Pirtobrutinib in BTK Inhibitor Pre-Treated Adult Patients with CLL/SLL July 12, 2023
Positive final KappaMab Ph2b study results in in kappa-type R/R multiple myeloma patients announced July 12, 2023
